NIVF is the ticker symbol for NewGenIvf Group Ltd, a publicly traded Healthcare sector company listed on Nasdaq. 13F Pro tracks NIVF with AI-powered analysis, a 32-signal quality score, SEC EDGAR financials, insider transactions, and institutional 13F holdings — all sourced directly from public SEC filings.

Is NIVF a good stock to buy?

NIVF is tracked on 13F Pro with SEC EDGAR data, but is not currently included in our 32-signal AI quality ranking. The full company profile with financials and AI insights is at https://13fpro.ai/company/NIVF.

Where does 13F Pro source NIVF data?

All NewGenIvf Group Ltd fundamentals and ownership data come directly from SEC EDGAR. NewGenIvf Group Ltd files with the SEC under CIK 1981662. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

NewGenIvf Group Ltd(NIVF)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2025-12-31.

NewGenIvf Group Ltd (NIVF) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. NIVF is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $23.7m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (FY 2025), NewGenIvf Group Ltd reports quarterly revenue of $4.7M, net income of $9.9M, free cash flow of $-11.1M. Top institutional holders of NIVF by reported 13-F value include Clear Street Group, MMCAP International SPC, Mint Tower Capital Management B.V., based on the most recent SEC filings. NIVF trades on the Nasdaq exchange and files with the SEC under CIK 1981662. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NIVF daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for NewGenIvf Group Ltd directly from SEC EDGAR.

Revenue

$4.7M

Net Income

$9.9M

Free Cash Flow

$-11.1M

NIVF key financials by period

NewGenIvf Group Ltd reported revenue, net income and margins by fiscal period, from SEC filings.
Period	Form	Revenue	Net income	Operating margin
FY 2025	20-F	$4.7M	$9.9M	—
FY 2024	20-F	$5.4M	$-524.6K	-21.4%
FY 2023	20-F	$5.1M	$130.2K	0.8%
FY 2022	20-F	$5.9M	$458.7K	6.7%
FY 2021	20-F	$4.1M	$-533.00	4.8%

Institutions holding NIVF

Institutional investors reporting a position in NewGenIvf Group Ltd on SEC Form 13F.
Institution	Shares	Value	Reported
Clear Street Group	389,270	$11.7K	2026-06-30
MMCAP International SPC	375,000	$11.3K	2026-06-30
Mint Tower Capital Management B.V.	150,000	$5.0K	2026-06-30
Walleye Trading	161,871	$4.9K	2026-06-30
D. E. Shaw	168,750	$4.2K	2026-06-30
RIVERNORTH CAPITAL MANAGEMENT	143,997	$2.8K	2026-06-30
TORONTO DOMINION BANK	50,000	$1.5K	2026-06-30
PERISCOPE CAPITAL	40,000	$1.2K	2026-06-30
CITADEL ADVISORS	28,216	$705.00	2026-06-30
Mariner	18,836	$565.00	2026-06-30

SEC EDGAR: CIK 1981662 →

NewGenIvf Group Ltd

NIVF

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $23.7M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.